• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Molecular Targeted Therapy Utilizing Galanin receptor type 2 signaling for Head and Neck Cancer

Research Project

Project/Area Number 26462620
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeMulti-year Fund
Section一般
Research Field Otorhinolaryngology
Research InstitutionJichi Medical University

Principal Investigator

Kanazawa Takeharu  自治医科大学, 医学部, 准教授 (20336374)

Co-Investigator(Kenkyū-buntansha) 水上 浩明  自治医科大学, 医学部, 教授 (20311938)
三澤 清  浜松医科大学, 医学部附属病院, 講師 (90334979)
Project Period (FY) 2014-04-01 – 2017-03-31
Project Status Completed (Fiscal Year 2016)
Budget Amount *help
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2016: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2015: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2014: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Keywords頭頸部癌 / 分子標的治療 / GPCR / アポトーシス / 分子標的治療薬
Outline of Final Research Achievements

To develop of the novel agents targeted for Galanin receptor type 2, the GALR2 was transfected and transduced into several head and neck squamous cell carcinoma (HNSCC) cell lines. The established stably GALR2 expressing HNSCC cells and adeno-associated virus vectors harboring GALR2 gene transduced cells were investigated the killing effect and signaling pathway after various GALR2 agonists. Galanin-like peptide (GALP) was the most powerful stimulator for GALR2 induced killing effect among some GALR2 agonists. All GALR2 agonists induced both cell cycle arrest and apoptosis, and GALP was the strongest apoptosis inducer. GALP and Galanin suppressed both MAP kinase pathway and PI3K/Akt pathway, but PI3K/Akt pathway suppression was observed in lower dose of GALP compared with Galanin. The killing effect was not observed after cetuximab alone, but the additional effects was observed in GALR2 stably expressing HNSCC cells.GALP would be potential agents for HNSCC therapy.

Report

(4 results)
  • 2016 Annual Research Report   Final Research Report ( PDF )
  • 2015 Research-status Report
  • 2014 Research-status Report
  • Research Products

    (4 results)

All 2017 2015 Other

All Int'l Joint Research (2 results) Journal Article (1 results) (of which Int'l Joint Research: 1 results,  Peer Reviewed: 1 results,  Open Access: 1 results,  Acknowledgement Compliant: 1 results) Presentation (1 results) (of which Int'l Joint Research: 1 results)

  • [Int'l Joint Research] ミシガン大学(米国)

    • Related Report
      2016 Annual Research Report
  • [Int'l Joint Research] ミシガン大学/耳鼻咽喉科/Thomas E. Carey 教授(米国)

    • Related Report
      2015 Research-status Report
  • [Journal Article] G-Protein-Coupled Receptors: Next Generation Therapeutic Targets in Head and Neck Cancer?2015

    • Author(s)
      Kanazawa T, Misawa K, Misawa Y, Uehara T, Fukushima H, Kusaka G, Maruta M, Carey TE
    • Journal Title

      Toxins

      Volume: 8 Issue: 8 Pages: 2959-2984

    • DOI

      10.3390/toxins7082959

    • Related Report
      2015 Research-status Report
    • Peer Reviewed / Open Access / Int'l Joint Research / Acknowledgement Compliant
  • [Presentation] Galanin Receptor 2 Utilizes Distinct Signaling Pathways to Suppress Cell Proliferation and Induce Apoptosis in HNSCC.2017

    • Author(s)
      Kanazawa T, Misawa K
    • Organizer
      9th Intrernational Conference on Head and Neck Cancer.
    • Place of Presentation
      Seattle
    • Year and Date
      2017-07-16
    • Related Report
      2016 Annual Research Report
    • Int'l Joint Research

URL: 

Published: 2014-04-04   Modified: 2022-06-09  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi